gsbr-5595

**GSBR-5595** is an investigational oral small molecule agonist of the glucagon-like peptide 1 receptor (GLP-1R), developed by Structure Therapeutics. Unlike most marketed GLP-1R agonists, GSBR-5595 is not a peptide but a small chemical compound, potentially improving patient convenience and accessibility compared to injectable GLP-1RA therapies. Preclinical studies have demonstrated that GSBR-5595 can improve motor coordination and increase dopaminergic neurons in mouse models of Parkinson's disease, suggesting neuroprotective effects beyond the typical metabolic actions of GLP-1R agonists. As of mid-2025, GSBR-5595 remains in the preclinical stage.